1. Adachi T, Hinoi T, Egi H, Shimomura M, Ohdan H (2015) Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery. Surg Today 45: 986–992. doi:
10.1007/s00595–014–1017-y
2. Ambrose N, MacDonald F, Young J, Thompson H, Keighley M (1989) Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer--can monoclonal antibodies do better? Eur J Surg Oncol 15: 99–102
3. Asare EA, Compton CC, Hanna NN, et al. (2016) The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer 122: 213–221. doi:
10.1002/cncr.29744
4. Averbach A, Jacquet P, u. Sugarbaker P (1994) Surgical technique and colorectal cancer: impaction on local recurrence and survival. Tumori 81 (3 Suppl): 65–71
5. Bachleitner-Hofmann T, Zitt M, Jäger T, et al. (ACO-ASSO), f. d. A. P. M. d. Ö. G. f. C. O. (2013) Leitlinie zur Behandlung von Patienten mit peritonealen Neoplasmen mittels zytoreduktiver Chirurgie und hyperthermer intraperitonealer Chemotherapie in Österreich.
www.aco-asso.at/arbeitsgruppen/ag-peritoneale-malignome/leitlinie-zur-behandlung-von-patienten-mit-peritonealen-neoplasmen-mittels-zytoreduktiver-chirurgie-und-hyperthermer-intraperitonealer-chemotherapie-in-oesterreich/